PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of eukcellPermissionsJournals.ASM.orgJournalEC ArticleJournal InfoAuthorsReviewers
 
Eukaryot Cell. 2012 April; 11(4): 452–462.
PMCID: PMC3318298

The SUMO E3 Ligase Siz2 Exerts a Locus-Dependent Effect on Gene Silencing in Saccharomyces cerevisiae

Abstract

In the yeast Saccharomyces cerevisiae, the two silent mating-type loci and subtelomeric regions are subjected to a well-characterized form of gene silencing. Establishment of silencing involves the formation of a distinct chromatin state that is refractory to transcription. This structure is established by the action of silent information regulator proteins (Sir2, Sir3, and Sir4) that bind to nucleosomes and initiate the deacetylation of multiple lysine residues in histones H3 and H4. Sir2 protein is a conserved histone deacetylase that is critical for mating-type and telomeric silencing, as well as a Sir3/4-independent form of silencing observed within the ribosomal DNA (rDNA) repeat locus. We report here that sumoylation plays an important role in regulating gene silencing. We show that increased dosage of SIZ2, a SUMO (small ubiquitin-related modifier) ligase, is antagonistic to gene silencing and that this effect is enhanced by mutation of ESC1, whose product is involved in tethering telomeres to the nuclear periphery. We present evidence indicating that an elevated SIZ2 dosage causes reduced binding of Sir2 protein to telomeres. These data support the idea that sumoylation of specific substrates at the nuclear periphery regulates the availability of Sir2 protein at telomeres.

INTRODUCTION

Eukaryotic chromosomes have distinct euchromatin and heterochromatin regions. Whereas euchromatin contains the bulk of the expressed regions of the genome, heterochromatin consists of transcriptionally silenced regions. The special chromatin modifications and the molecular processes that contribute to and maintain these states have been studied extensively using several model systems, including budding yeast, fission yeast, and Drosophila (22, 43, 54). In the budding yeast Saccharomyces cerevisiae, transcriptionally silenced chromatin is found at HML and HMR (HM loci), the two silent mating-type loci, at the telomeres, and at the ribosomal DNA (rDNA). Transcriptional repression at HM loci is initiated by silencer elements E and I, which flank the two loci. The HMR-E silencer, which is most well studied, consists of about 150 bp of DNA that contains binding sites for three different sequence-specific DNA-binding proteins: origin recognition complex (ORC), Rap1, and Abf1. These silencer-bound proteins recognize and recruit four silent information regulator (SIR1 to -4) proteins that bind to chromatin. Our current understanding is that multiple interactions between silencer-binding proteins, SIR proteins, and nucleosomes establish and maintain silenced chromatin (8, 18).

Sir1 is specifically required for the establishment of silent chromatin at HM loci through direct interactions with Orc1 and Sir4 (4, 53). Sir4 and Sir3 proteins are recruited through interactions with Rap1 and are stabilized by interactions among them (36). Sir4 also recruits Sir2 protein, an evolutionarily conserved NAD-dependent histone deacetylase that removes acetyl groups from histone tails in adjacent nucleosomes. Because Sir3 protein binds with higher affinity to a histone H4 N-terminal tail in which K16 is deacetylated (24), one current model proposes that SIR complexes spread to adjacent deacetylated nucleosomes, recruiting more Sir2 protein and thus initiating a cycle of deacetylation and nucleosome binding by the SIR complex (reviewed in reference 43). Silencing at telomeres appears to follow a similar mechanism, apart from some differences in the recruitment of SIR proteins. The truncated telomeres used in most studies of telomere position effect (TPE) do not engage Sir1 in the Sir2/3/4 recruitment process and also display unstable silencing. Instead, telomeres use the Yku70/80 heterodimer to recruit Sir proteins (specifically interacting with Sir4), together with Rap1, which binds with high affinity to the telomere repeat sequences at all chromosome ends (29, 35). Interestingly, silencing can be improved by the artificial tethering of Sir1 (11) at truncated telomeres, and Sir1 is required for silencing at native telomeres (40). Silencing at both telomeres and HM loci is not promoter specific but does appear to be competed by strong activators (3, 59). Furthermore, boundary elements counteract the spreading of silent chromatin into euchromatin sites (16).

A different form of gene silencing has been described that affects RNA polymerase II (RNAP II) promoters found naturally (or more often placed artificially) within the rDNA locus. This form of transcriptional silencing requires the Sir2 deacetylase but is independent of Sir1, Sir3, and Sir4, suggesting a mechanism different from the one that operates at HM loci and telomeres (6, 45, 46).

SUMO (small ubiquitin-related modifier, encoded by SMT3 in yeast) is an ~100-amino-acid protein, structurally similar to ubiquitin, that is added posttranslationally to proteins (34, 38, 55, 62, 64). Sumoylation is a dynamic and reversible process. SUMO modification of proteins alters their protein-protein interactions, protein-DNA interactions, subcellular localization, or susceptibility to ubiqutination. Sumoylation regulates a variety of cellular processes, including DNA replication and repair, transcription, chromosome segregation, intracellular transport, and apoptotic signaling. Several targets of SUMO have been identified through genome-wide screens, but the functional significance of most targets awaits elucidation (14, 23, 39, 56, 66). However, a critical role of sumoylation has been demonstrated for several proteins, including PCNA, Rad18, Rad52, and p53 (5, 26, 44, 57).

The conjugation of SUMO to target proteins, similarly to ubiquitin, is achieved by the action, in series, of three enzymes involved in activation (E1), conjugation (E2), and ligation (E3) reactions. SUMO is synthesized as a precursor and is processed at the C terminus by an isopeptidase (Ulp1) to reveal a di-glycine motif that is used for conjugation. The mature SUMO is activated in an ATP-dependent manner by the E1 enzyme (a heterodimer of Aos1 and Uba2 in yeast) followed by conjugation to the E2 enzyme (Ubc9) and finally ligation to the epsilon amino group of a lysine residue in the target protein by E3 ligases. The S. cerevisiae genome encodes a single SUMO (SMT3), E1 (AOS1/UBA2), and E2 (UBC9) but has at least four known E3 ligase genes, SIZ1, SIZ2, MMS21, and ZIP3. Mammals have several SUMO variants and E3 ligases (reviewed in reference 34). There are also two known isopeptidase genes in yeast, ULP1 and ULP2, whose products are required for both SUMO processing and cleaving SUMO from target proteins (desumoylation). In yeast, only Ulp1 is required for processing precursor SUMO to its mature form, although both Ulp1 and Ulp2 are involved in desumoylating target proteins. Sumoylation is therefore rapid and transient and is controlled by regulated activity of sumoylating and desumoylating enzymes.

In the context of transcriptional regulation, sumoylation has been shown to promote both repression and activation through diverse mechanisms (19, 28, 31, 37). In this work, we report a connection between sumoylation and heterochromatin establishment in yeast. We show that an elevated dosage of a gene coding for a specific SUMO ligase, SIZ2, disrupts silencing in yeast. This effect is exacerbated by a mutation in ESC1, which encodes a nuclear envelope protein involved in multiple processes, including anchoring of telomeres to the nuclear periphery, mRNA transport, and DNA repair. We also show that this effect is associated with reduced occupancy of heterochromatin by Sir2 protein, the conserved histone deacetylase critical for establishment of heterochromatin and, to a lesser extent, Sir4. We propose that sumoylation by Siz2 at the nuclear periphery either directly or indirectly influences the function of Sir2 at telomeres and HM loci.

MATERIALS AND METHODS

Strains and plasmids.

All strains used in this study are isogenic with W303. The genotypes of the strains used are described in Table 1. Manipulations in the yeast strains, such as gene knockouts or protein tagging, were carried out by PCR-based homologous recombination (32) and were confirmed by Southern blotting. All mutations described here are full-length gene (open reading frame [ORF]) replacements. The epitope-tagged strains were confirmed to be functional by telomere length and mating assays. Gal4 binding domain (Gbd) fusion proteins with Rap1 and Sir4 were described previously (7, 33). Gbd-Yif1 is a gift from R. Sternglanz (1). The multicopy SIZ2 plasmid was constructed by digesting D4 genomic library plasmid with XhoI. The full-length SIZ2 gene along with its promoter region was thus isolated and ligated into SalI-cut Yeplac181 (CKM6), a 2μm vector that contains the LEU2 selectable marker. The full-length MMS21 gene along with its promoter was amplified by PCR and cloned into BamHI- and SalI-digested yEPLac181 vector. Full-length SIZ1 along with its promoter was subcloned from pT-23 (51) into yEPLac181 by digestion with PstI and SalI. Quantification of silencing levels was carried out by plating out cells from at least three independent transformants on control plates (Sc-Leu) and test plates (Sc-Leu Trp or Sc-Leu with 5-fluoroorotic acid [5-FOA] added) and computing the average of fraction repressed or derepressed. Site-directed mutagenesis was performed using Stratagene QuikChange kit and confirmed by DNA sequencing.

Table 1
List of the yeast strains used in this studya

mRNA analyses.

Total RNA was prepared from logarithmically growing cells (optical density at 600 nm [OD600] of 1) using a RiboPure-Yeast kit (Ambion) and treated with RNase free DNase. Two micrograms of RNA was taken, and cDNAs were prepared using a high-capacity reverse transcription kit (Applied Biosystems) and used as the template for the real-time PCR using Sybr green PCR master mix (Applied Biosystems). The primers were designed and PCR was performed as described before (13, 61). Quantification was performed using the comparative threshold cycle (CT) method. Graphs were plotted from the average of three experiments, and error bars show standard deviations.

Analysis of sumoylation.

Enrichment of sumoylated proteins was done essentially as described in reference 9. Briefly, myc-tagged strains containing 8×His-tagged SUMO were grown to an OD600 of 1, pelleted, and frozen in liquid nitrogen. Equal amount of cells were thawed in NaOH, precipitated with trichloroacetic acid (TCA), and resuspended in guanidinium hydrochloride, and an equal amount of protein from this was incubated with nickel beads. Beads were washed thoroughly and boiled in SDS buffer and then separated by SDS-PAGE. Western blots were probed with anti-myc antibody. The myc-tagged strains without 8×His-tagged SUMO were used as controls to ensure specificity of the SUMO enrichment, and slower-moving bands were never detected in these strains. Comparisons of slower-moving sumoylated proteins were made between strains containing empty vector and those containing SIZ2 plasmid.

Fluorescence microscopy.

Immunofluorescence was done as described previously (20, 35). Briefly, cells grown in appropriate media were fixed with paraformaldehyde, spheroplasted, and spotted on multiwell slides. They were further permeabilized with methanol and acetone and then blocked with 1% ovalbumin in phosphate-buffered saline (PBS). Cells were incubated with appropriate primary antibody dilutions overnight at 4°C and then washed thoroughly and incubated with the recommended dilutions of fluorescently labeled secondary antibody. After washes, slides were mounted in mounting medium containing DAPI (4′,6-diamidino-2-phenylindole) and then viewed and photographed in a Leica (AOBS) TCS SP5 system and analyzed using LAS AF software version 2.2.0.

ChIP.

At least three independent chromatin immunoprecipitation (ChIP) experiments were done by growing KRY109 and KRY295 transformed cells with empty vector or SIZ2 in 50 ml of Sc-Leu minimal medium until an OD600 of 1.5 to 1.0, as described in reference 60. Briefly, cells were cross-linked with 1.4 ml of 37% formaldehyde, and cross-links were quenched with 3.4 ml of 2 M glycine. Then cells were pelleted and washed with ice-cold Tris-buffered saline (TBS). Cells were lysed in 400 μl of ice-cold lysis buffer with protease inhibitor (0.1% deoxycholic acid, 1 mM EDTA, 50 mM HEPES-KOH [pH 7.5], 140 mM NaCl, 1% Triton X-100) by addition of an equal volume of glass beads and vortexing at maximum speed for 10 min at 4°C. Lysate was sonicated in a Biorupter sonifier to shear the chromatin to an average length of 500 to 800 bp. The samples were then clarified, and the supernatant was precleared by adding a 30-μl bed volume of protein A-Sepharose beads (Amersham Biosciences). Sample was centrifuged at 7,500 rpm for 5 min at 4°C, and the supernatant was aliquoted equally into two tubes. At this point, 50 μl of sample was taken in a fresh tube and used as input DNA. Primary antibody against the Myc epitope (Abcam) or Sir2 protein was added to the sample, and the sample was incubated overnight at 4°C with constant rotation. Thirty microliters of protein A-Sepharose beads was added to the chromatin-antibody mixture and incubated for 2 h at 4°C with constant rotation. Protein A-Sepharose beads were washed with 1 ml of each lysis buffer, lysis-500 buffer, LiCl-detergent solution (0.5% deoxycholic acid, 1 mM EDTA, 250 mM NaCl, 0.5% NP-50, 10 mM Tris-HCl [pH 8.0]), and TBS buffer. Chromatin immunoprecipitate was eluted first with 100 μl of 1% SDS in Tris-EDTA (TE: 10 mM Tris-HCl [pH 8.0], 1 mM EDTA [pH 8.0]) and then with 150 μl of 0.67% SDS in TE buffer by incubation at 65°C for 10 min. DNA from bound and unbound chromatin (input sample) was purified by phenol-chloroform-isoamyl alcohol extraction and ethanol precipitation. A total of 150 ng of DNA sample from ChIP experiments was analyzed by real-time PCR using Sybr green master mix (Applied Biosystems) according to the manufacturer's instructions on an Applied Biosystems 7500 HT fast real-time PCR system. The primers used are located on the end of chromosome VI-R and reported in reference 60. Relative quantification of immunoprecipitated DNA was done based on the comparative CT value method using sequence detection software. Statistical significance of differences in binding of Sir proteins in the presence and absence of Siz2 was evaluated by performing a Mann-Whitney U test. The P values reported were obtained using data from at least four independent experiments.

RESULTS

Genetic screen for factors that disrupt Sir protein localization at the nuclear periphery.

Previous studies have shown that mutations in HMR locus silencer elements (ORC, Rap1, or Abf1 binding sites) that abolish repression can be bypassed by tethering of Sir proteins to the deleted silencers in the form of Gal4 DNA-binding domain (Gbd) fusions (11, 33). Remarkably, silencer mutations can also be bypassed by tethering of the locus to the nuclear periphery, through overexpression of several different Golgi apparatus/endoplasmic reticulum (ER) proteins, such as Yif1, Yip1, and Yip3, fused to Gbd (1). Targeted silencing by these Gbd fusion proteins is also Sir dependent and requires at least one functional silencer element at the HMR-E silencer. It was hypothesized that these proteins establish silencing by placing the defective HMR locus in the milieu of Sir proteins, which normally accumulate at the nuclear periphery.

If silencing by these Gbd fusion proteins is dependent on Sir protein accumulation at the periphery, then loss of Sir proteins at the periphery should lead to loss of silencing by these proteins. We tested this in a yku70 mutant background where peripheral localization of Sir proteins is abolished (29). YSB35, a yeast strain that has the E and B elements of the HMR-E silencer replaced with three Gbd binding sites (UASg) and the HMRa1 gene replaced with TRP1 (1), was transformed with Gbd, Gbd-Sir4, and Gbd-Yif1. As shown in Fig. 1A, expression of either Gbd-Yif1 or Gbd-Sir4 in this strain confers a Trp phenotype, indicating that both hybrids can induce silencing of the TRP1 gene. However, in the same strain now containing a yku70 mutation (KRY223), Gbd-Yif1 is unable to silence TRP1, whereas Gbd-Sir4 is still able to do so. This confirms the hypothesis that targeted silencing by Gbd-Yif1 is dependent on the accumulation of Sir proteins at the nuclear periphery.

Fig 1
Gbd-Yif1-mediated silencing targeted silencing is affected by elevated SIZ2 dosage. (A) Gbd, Gbd-Sir4, and Gbd-Yif1 were transformed into the WT (YSB35) and yku70 (KRY223) strains. Cultures were grown, and 5 μl of 10-fold serial dilutions of each ...

In order to identify novel proteins that are involved in maintaining Sir protein accumulation at the nuclear periphery, we set up a screen for factors that when overexpressed would lead to a decrease or loss of silencing by Gbd-Yif1. Briefly, YSB35 expressing Gbd-Yif1 was transformed with a yeast genomic library in a high-copy-number vector (a gift from K. Nasmyth) and screened for transformants that showed robust growth on medium lacking tryptophan. We isolated a plasmid from one candidate transformant (named D4) that reproducibly conferred a modest level of derepression of the TRP1 marker (Fig. 1B). Sequencing of D4 revealed that it contained the chromosomal region encompassing ISN1, SIZ2, PUP1, SME1, and PET123. In order to identify which of these genes is responsible for derepression, we separated them. We first tested if SIZ2 was responsible for derepression. Indeed, we found that SIZ2 alone on a high-copy-number plasmid abrogated the targeted silencing by Gbd-Yif1 to the same level as plasmid D4 (Fig. 1B).

Elevated gene dosage of SIZ2 causes loss of gene silencing.

Transcriptional silencing at HM loci and telomeres (referred to hereafter as telomere position effect, or TPE) is established and maintained by very similar mechanisms. Therefore, in order to confirm and extend the observations that elevated SIZ2 dosage disrupts targeted silencing by Gbd-Yif1, we tested its effect on TPE. KRY12, which contains a modified telomere on the left arm of chromosome VII (TelVIIL), with a URA3 gene inserted adjacent to telomere repeats, was used to assay TPE (21). Silencing of the URA3 gene allows strains to grow on plates containing the drug 5-fluoroorotic acid (5-FOA). As shown in Fig. 2A, when the SIZ2-containing plasmid was introduced (row 2), growth on 5-FOA was reduced significantly, suggesting that elevated SIZ2 dosage affects silencing at telomeres as well.

Fig 2
Elevated SIZ2 reduces silencing at telomeres and HMR but not rDNA. KRY12 and YDW 126 were transformed with empty vector (−), SIZ2, SIZ1, or MMS21 in a 2μm plasmid. In the top panel, 10-fold serially diluted KRY12-derived cells were plated ...

Siz2 belongs to a conserved class of SP-ring-containing E3-like SUMO ligases (25, 27, 51). Four SUMO ligases have been identified in yeast: Siz1, Siz2, Mms21, and Zip3. Siz1 and Siz2 account for most of the protein sumoylation observed in vivo (41). Mms21 sumoylates several proteins involved in chromosome stability (65), and Zip3 is a meiosis-specific E3 ligase (10). We tested if elevated gene dosage of any of the other mitotic E3 ligases also had the same effect as SIZ2 or if the effects were specific to SIZ2. The SIZ1 and MMS21 genes were cloned in a multicopy vector, transformed into KRY12, and assayed for TPE. As shown in Fig. 2A, expression of SIZ1 and MMS21 had marginal effects on TPE, as indicated by good growth on plates containing 5-FOA, whereas the SIZ2 plasmid strongly reduced TPE, as indicated by poor growth on 5-FOA plates. These observations show that TPE loss is largely SIZ2 specific and suggest that a substrate unique to Siz2 might be affected. They also rule out any global effects due to elevated dosage of SUMO ligases in general.

To extend this observation further, we tested silencing at the HMR locus directly, using a strain containing a weakened silencer (HMR-ΔaEB) linked to the TRP1 reporter that had been shown previously to be a sensitive indicator of silencing at HMR (49). This strain (YDW126) was transformed with either empty vector or vector containing one of the three ligase genes and tested for expression of TRP1 by plating on medium lacking tryptophan. We found a small but reproducible reduction in TRP1 silencing with increased SIZ2 dosage, but not SIZ1 or MMS21 (Fig. 2B, lower panel). Taken together, these results indicate that elevated SIZ2 dosage interferes with gene silencing at both telomeres and the HMR locus.

Elevated SIZ2 gene dosage does not reduce silencing at rDNA locus.

In Saccharomyces cerevisiae, apart from telomeres and HM loci, the other predominant silent region, with respect to RNAP II-driven transcription, is the rDNA locus. Silencer protein Sir2 is a NAD-dependent deacetylase involved in silencing telomeres, HM loci and the rDNA locus. However, the mechanism involved in establishing and maintaining silent chromatin at the rDNA locus is different from that of telomeres and HM loci and is dependent on Sir2 but not Sir3 or Sir4. Sir2 protein is sequestered by Net1p to the RENT complex, which is required for rDNA silencing (48). Since our results show that elevated SIZ2 gene dosage reduces silencing both at telomeres and HMR, we asked whether SIZ2 also affects silencing at the rDNA locus. To test this, we introduced the three E3 ligases (SIZ2, SIZ1, and MMS21) or an extra copy of SIR2 into KRY458 (rDNA::mURA3-HIS3) and subjected them to silencing assay on 5-FOA medium (Fig. 2C). The silencing phenotypes of the three ligases were indistinguishable from that of the vector-alone control, showing that elevated SIZ2 dosage has no detectable effect on rDNA silencing, although the extra copy of SIR2 improves silencing, as expected.

esc1 mutation exacerbates gene silencing defects caused by elevated SIZ2 gene dosage.

In order to gain insights into the molecular pathways involved in this process, we tested the effect of elevated SIZ2 dosage in different mutant backgrounds. We generated yku70, yku80, and esc1 deletion mutations in tethered silencing reporter strain YSB35. These mutations were chosen because the corresponding proteins have been shown to be involved in anchoring telomeres to the nuclear periphery (29, 50). Gbd, Gbd-Sir4, and Gbd-Yif1 were transformed into these strains. We also tested Gbd-Sir4-mediated silencing because Gbd-Yif1-mediated silencing is compromised in these strains due to reduced anchoring of telomeres to the nuclear periphery (our unpublished observations and Fig. 1). In the esc1 strain, when only empty vector is cotransformed, Gbd-Rap1, Gbd-Sir4, and Gbd-Yif1 establish strong silencing (Fig. 3A; see the wild-type [WT] control in Fig. S1 in the supplemental material). However, upon cotransformation with a high-copy SIZ2-containing plasmid, all hybrids, including Gbd-Rap1 and Gbd-Sir4, were unable to establish silencing, as seen by the increased growth on plates lacking tryptophan. In the yku70 and yku80 mutants, though, Gbd-Sir4-mediated silencing was hardly affected by increased SIZ2 gene dosage (Fig. 3B). The same results were obtained with Gbd-Rap1 and Gbd-Sir3 (data not shown).

Fig 3
esc1 mutation exacerbates silencing defects of elevated SIZ2 dosage. (A) Targeted silencing in the esc1 mutation containing an elevated gene dosage of SIZ2. KRY213 was cotransformed with plasmids expressing either Gbd or one of the Gbd fusion proteins ...

As targeted silencing by all of the hybrids was reduced in esc1 mutants, we tested the effect of elevated dosage of the other SUMO ligases in esc1 mutants on gene silencing. We deleted the ESC1 gene in KRY12 and transformed this strain with either empty vector or vector containing any one of the SUMO ligases. Again we saw a significant loss in TPE with increased SIZ2 dosage (Fig. 4A). TPE also appeared to be partially sensitive to overexpression of other SUMO ligases in the esc1 background.

Fig 4
Loss in silencing is most pronounced in SIZ2 overexpression. KRY341 (A) and KRY354 (B) were transformed with the SUMO ligases SIZ1, SIZ2, or MMS21 or empty vector (−) on 2μm plasmid. The silencing assay for HMR and telomeres was done as ...

We next tested the effect of these ligases and esc1 mutation on silencing at the HMR locus. The esc1 mutation was introduced into the HMRΔaEB::TRP1 strain. The SUMO ligases were introduced into this strain, and the expression of TRP1 was analyzed (Fig. 4B). Here we observed a dramatic loss in TRP1 silencing with elevated SIZ2 dosage, with slight increases in TRP1 derepression by increased SIZ1 dosage as well, echoing the TPE findings, although in this case, MMS21 had no effect. These data further confirm the observation that silencing is severely compromised in esc1 mutants with increased SIZ2 dosage. Esc1 is also involved in localizing Ulp1, the desumoylating enzyme, to the nuclear periphery, and loss of esc1 leads to redistribution of Ulp1 (30).

Abrogation of gene silencing requires catalytically active Siz2.

As increased gene dosage of SIZ2 affected gene silencing specifically only in esc1 mutants among all the mutants tested, we asked if elevated gene dosage of SIZ2 really affected sumoylation. Using Northern blots, we first confirmed that elevated dosages of SUMO ligases did increase the expression of these genes. RNA was extracted from cells expressing either vector alone or any one of the three SUMO ligases. We found that all three genes were overexpressed in strains containing elevated doses; the ethidium-stained agarose gel serves as a loading control (see Fig. S2 in the supplemental material). We then tested if the increased dosage of SIZ2 altered the SUMO proteome by performing Western blots using anti-SUMO antibodies. We found that many proteins showed increased sumoylation with elevated SIZ2 dosage, further indicating that increased dosages of SIZ2 altered the sumoylation status of many proteins (see Fig. S3 in the supplemental material). We then tested if this catalytic activity of Siz2 was essential for the phenotypes observed directly by mutating the catalytic domain of Siz2. Siz2 belongs to the class of SP-RING domain-containing enzymes and has the conserved cysteine and histidine (C379 and H377) residues in the catalytic site. As other SUMO ligases with mutations in these residues lose their catalytic activity (58), we incorporated the same mutations into Siz2. We transformed this mutant SIZ2 into the wild type and esc1 mutants and tested the silencing phenotype at both the telomeric reporter and the HMR locus. As shown in Fig. 5A and B, the mutant SIZ2 is similar to the vector control, whereas wild-type SIZ2 abrogates silencing at telomeres and HMR, as expected. These data strongly support our conclusion that elevated SIZ2 dosage reduces gene silencing by sumoylation of target protein(s).

Fig 5
Catalytically active Siz2 is essential for inducing silencing defects. The KRY12 (WT), KRY341 (esc1::KANMx), and KRY354 strains were transformed with either empty vector (−), SIZ2, or CH-SIZ2 on the 2μm plasmid. The silencing assay for ...

Elevated SIZ2 dosage leads to derepression of native silenced loci.

Our results strongly suggest that increased SIZ2 dosage disrupts silencing, as measured by growth assays. Recently, two reports have suggested that the 5-FOA growth assays may not be true indicators of silencing (42, 52). We therefore tested the silencing of a native subtelomeric gene, yFR057w, previously shown to be silenced in a Sir protein-dependent manner (61). We isolated RNA from wild-type and esc1 mutant cells transformed with either empty vector, one of the SUMO ligases, or the catalytically inactive SIZ2 and performed quantitative reverse transcripatase PCR (RT-PCR). As shown in Fig. 6A and B, the RT-PCR data correlate with the growth-based assays reported above. Cells transformed with empty vector do not show derepression, whereas as expected, the sir2 mutant shows complete derepression. In wild-type cells, elevated SIZ2 dosage leads to a 4-fold increase in yFR057w, while all other plasmids show no effect. In esc1 deletion, SIZ2 shows a large increase in derepression and similar to our observation in growth assays, SIZ1 too shows a small increase in derepression. We also tested the repression at the wild-type silent mating-type loci in wild-type (data not shown) and esc1 mutant cells transformed with the same set of plasmids (Fig. 6C). There was no detectable increase in derepression in wild-type cells; however, in esc1 mutant cells, SIZ2 overexpression showed elevated derepression. This increase appears modest in comparison to the growth assays, because unlike in growth assays where we have used a weakened silencer that is more sensitive to perturbations, this assay was done on the strong wild-type silencer. Thus, these data further firmly establish that elevated SIZ2 dosage leads to derepression of silencing at the native loci as well.

Fig 6
Transcription of native silent loci. Transcription of yFR057w or HMRa1 was quantified by reverse transcription and real-time PCR analysis for wild-type cells (A) and esc1 mutants (B and C) containing the indicated 2μm plasmids (x axis). Signals ...

Elevated SIZ2 gene dosage increases sumoylation of proteins involved in silencing.

As our previous experiments strongly suggested elevated SIZ2 dosage increased sumoylation of target proteins, we directly tested this. Previous whole-proteome studies have shown that Yku70, Yku80, Sir4, and Sir3 are sumoylated. We tested if the sumoylation of these proteins was affected upon elevated SIZ2 dosage. All four proteins were C-terminally tagged with myc eptiopes and 8×His-tagged SUMO was substituted in the place of endogenous SUMO (9). Each of these strains was transformed with either empty vector or SIZ2, and total protein was extracted and enriched for sumoylated proteins using a nickel column as reported earlier (9). We detected the myc epitope-tagged proteins using an anti-myc antibody. We found that all four proteins showed slower-migrating bands in the SUMO-enriched proteome. Interestingly, we found either additional or increased intensity of some of the slower-moving bands upon increased SIZ2 dosage compared to vector alone in the tested proteins, albeit to different degrees (Fig. 7). This effect is most prominent for Sir3 and Sir4, where the upper (presumably sumoylated) band intensity increases to the level of intensity of the lower band upon increased SIZ2 dosage, whereas in the presence of vector alone, the upper band intensity is less than the intensity of the lower band. These data provide evidence that sumoylation of multiple proteins involved in silencing is increased upon elevated SIZ2 dosage.

Fig 7
Sumoylation of target proteins by Siz2. The 8×His-tagged SUMO strains containing myc-epitope-tagged Yku70, Yku80, Sir3, or Sir4 were transformed with empty vector or 2μm SIZ2 plasmid, and total sumoylated proteins were enriched on a nickel ...

Elevated SIZ2 gene dosage does not cause delocalization of telomeric proteins.

Having established that ESC1 deletion exacerbates the silencing defects caused by elevated SIZ2 dosage, we investigated the mechanism through which these effects are manifested. Because SUMO modification of proteins can alter their subcellular localization or stability, we asked whether Sir2 or Sir4 localization is affected by elevated SIZ2 dosage. Wild-type and esc1 derivatives of a strain expressing Sir4-Myc from the endogenous SIR4 locus were used for these experiments, and both Sir2 and Sir4 were localized by indirect immunofluorescence (20). Figure 8 shows the localization of Sir4 protein in both wild-type and esc1 strains with and without elevated SIZ2 dosage. The nuclear rim was stained with antibodies to Nsp1 protein, a component of the nuclear pore complex. As expected, Sir4 was found concentrated in 4 to 6 foci per nucleus, representing the telomeres, in wild-type cells. However, we could detect no differences in Sir4 protein localization upon elevated SIZ2 dosage in the wild type or in esc1 mutants. These results show that the loss in silencing is not due to loss of Sir4 protein localization. Sir2 protein localization in the same strains was examined using antibodies to Sir2 protein. As shown in Fig. 9, Sir2 shows a prominent nucleolar localization (red, arc-like staining), with weaker telomeric spots visible in some cells. This localization was not detectably altered in esc1 mutants or upon elevated SIZ2 dosage. We also confirmed by Western blot analysis that stability of these proteins was not affected by SIZ2 overexpression in either wild-type or esc1 strains (see Fig. S4 in the supplemental material).

Fig 8
Elevated SIZ2 does not visibly alter Sir4p localization. Immunolocalization of Sir4 protein was done in the WT and esc1 mutants containing either empty plasmid (columns 1 and 3) or 2μm SIZ2 (columns 2 and 4). Anti-myc antibody (red) was used to ...
Fig 9
Elevated SIZ2 gene dosage does not visibly alter localization of Sir2 protein. Immunolocalization of Sir2 protein was done in the WT and esc1 mutants containing either empty plasmid (columns 1 and 3) or 2μm SIZ2 (columns 2 and 4). Anti-Sir2 antibody ...

Elevated gene dosage of SIZ2 affects Sir2 localization at telomeres.

As immunofluorescence techniques can detect only major changes in localization, we assessed the association of Sir4 and Sir2 proteins with the telomeres through the more sensitive and quantitative ChIP technique (47, 60), using PCR primers to detect unique sequences from 0.5 kb to 5 kb internal to chromosome VI-R (60). The same immunoprecipitated DNA was also used to amplify a euchromatic internal gene, SPS2, where Sir proteins are not expected to bind. This served as an internal control to assess the amount of DNA precipitated due to nonspecific interactions (Fig. 10A). As expected, both Sir2 and Sir4 were highly enriched at the very ends of the telomere and decreased rapidly toward the centromere. Telomere association of Sir4 and Sir2 was largely unaffected by elevated SIZ2 gene dosage in wild-type strains (see Fig. S5 in the supplemental material). These data are consistent with the immunofluorescence data and indicate that Sir4/Sir2 protein association with telomeres is at most only very mildly affected by elevated SIZ2 dosage in wild-type cells.

Fig 10
Elevated SIZ2 gene dosage affects association of Sir2/4 protein with telomeres and HMR in esc1Δ. Chromatin from the indicated transformants was precipitated with anti-myc antibody for Sir4 protein (A) and polyclonal antibody for Sir2 protein (B). ...

However, when the esc1 strains were tested for Sir4/Sir2 protein localization, we detected some differences. As shown in Fig. 10A, the association of Sir4 was reduced slightly at internal sites of 2.5 kb and 3.5 kb from the telomere, although not detectably affected at the most proximal site tested. On the other hand, Sir2 protein association with the telomeric chromatin was reduced by half upon overexpression of Siz2 at all sites examined, including the most proximal site. These differences (at most 2-fold) are likely undetectable by the immunofluorescence method we have used. However, this reduction in binding of Sir2 protein is statistically significant, as P values at all sites were <0.05 (Fig. 10B). As the maximum derepression due to elevated SIZ2 dosage was seen in the esc1Δ HMRΔa strains, we also tested the association of Sir2 and Sir4 with the HMR locus. As shown in Fig. 10C, there was a significant reduction in association of both proteins with this locus. Therefore, it appears that increased doses of SIZ2 lead to a reduction of Sir2 protein association at the telomeres and both Sir2 and Sir4 protein at the HMR locus.

DISCUSSION

Elevated SIZ2 gene dosage disrupts silencing at telomeres and the HMR locus.

Here we show that sumoylation influences gene silencing at telomeres and HM loci in S. cerevisiae. Elevated gene dosage of SIZ2, which encodes an E3 SUMO ligase, reduces silencing at both the loci. The catalytic activity of Siz2 is essential for this phenotype, strongly suggesting that it results from sumoylation of one or more Siz2 substrates. Increasing gene dosage of the two other known mitotic SUMO ligases in yeast (Siz1 and Mms21) has a much weaker effect on silencing, implying that an Siz2-specific substrate may be involved. However, it is possible that under the conditions described here, Siz1 and especially Mms21, which is known to function in a complex with Smc5/6, do not confer the same amount of increased sumoylation activity as Siz2 and are therefore unable to influence gene silencing.

esc1 exacerbates the silencing defect of elevated SIZ2 gene dosage.

Significantly, we found that the silencing defect induced by increased SIZ2 dosage is enhanced by deletion of ESC1. Esc1 is a large coiled-coil protein associated with the inner nuclear membrane that was discovered in a screen for proteins that establish silencing when targeted to a defective HMR locus (2). esc1 mutants per se show only a slight loss in TPE (Fig. 4A, row 1) (2). However, under conditions of increased SIZ2 gene dosage, esc1 mutants show a complete loss of TPE and HMR silencing. Esc1 interacts with Sir4 and is required for the anchoring of telomeres to the nuclear periphery (50). Esc1 also influences SUMO metabolism by maintaining a uniform nuclear periphery localization of Ulp1, the SUMO isopeptidase that removes SUMO from target proteins. In the absence of Esc1, Ulp1 is mislocalized to discrete domains on the nuclear envelope (30, 38). It is most likely that this property of Esc1 to anchor Ulp1 to the nuclear periphery is the reason for enhancement of the Siz2 overexpression phenotype. This suggests that the desumoylating activity of Ulp1 at the nuclear periphery maintains a balance of sumoylation that is perturbed in the esc1 mutant.

Elevated SIZ2 gene dosage affects Sir2 binding at telomeres.

Elevated SIZ2 dosage alters Sir2, and to a much smaller extent Sir4, binding to telomeres, particularly in the absence of Esc1. Binding of both proteins is reduced at the HMR-E silencer. This suggests that Siz2 overexpression influences gene silencing by interfering with Sir2 and perhaps Sir4 association with heterochromatin. Two recent reports also link silencing to sumoylation via Sir2 (13, 63) Deletion of the SUMO isopeptidase gene ULP2 leads to a loss of telomere silencing, although its effect on HMR was not reported (13). Furthermore, deletion of SLX5, which leads to increased overall sumoylation, also reduced gene silencing. This work also indicated that the effects of ULP2 and SLX5 mutation are linked to Sir2, further supporting our observation that SUMO homeostasis is important for gene silencing and, more specifically, for the function of Sir2. Ulp2 is localized throughout the nucleus, whereas Ulp1 is mostly at the nuclear periphery, and this localization is dependent on Esc1. Based on our data, we predict that elevated SIZ2 dosage causes increased sumoylation of target proteins at the nuclear periphery that leads to a loss in silencing. Esc2, a protein that physically interacts with Sir2 (12) and has SUMO-like motifs, influences gene silencing in a locus-dependent manner (15, 63). As Esc2 interacts with both Sir2 and SUMO and also influences the association of Sir2 protein with telomeric heterochromatin, it could potentially be one of the targets for Siz2-mediated silencing defects.

When this article was in preparation, two reports appeared which showed that Siz2 sumoylates multiple substrates at the nuclear periphery and telomeres, including Yku70/80, Rap1, Cdc13, and Sir4. The anchoring of telomeres to the nuclear periphery was shown to be dependent on sumoylation of Yku70/80. Other possible substrates, such as Esc1, Sir3, and Sir2, which are also known to be sumoylated (23, 56), were not tested. Relevant to the work presented here, these studies show that Siz2 functions at the nuclear periphery and has multiple substrates. Second, Siz2 affects telomere organization and function through modification of these substrates. Although these studies were focused on the role of Siz2 in telomerase function and did not study silencing, our work suggests that sumoylation by Siz2 also influences heterochromatin at telomeres, by decreasing the association of Sir2 with these loci. Our studies show that several proteins could be potential targets, and identification of the substrate(s) of Siz2 that influences gene-silencing properties by specifically mutating each of the multiple potential sumoylation sites in these proteins will be important to understand the mechanistic basis of how Sir protein association and heterochromatin establishment are influenced by SUMO metabolism. We favor the idea that sumoylation on one or more targets either directly or indirectly influences the Sir2 association with the heterochromatin.

Interestingly, although TPE and HMR silencing are reduced upon Siz2 overexpression, rDNA silencing is not detectably affected under these conditions. This finding is somewhat puzzling, since Siz2 overexpression caused reduced binding of Sir2 at telomeres, and Sir2 is the one Sir protein that is also required for rDNA silencing. One explanation for this apparent discrepancy is that Siz2 overexpression affects Sir2 exclusively (or most strongly) at the nuclear periphery, with nucleolar pools of Sir2 remaining largely unaffected. This is partly supported by the report described above, which showed that telomeres present in the nuclear interior were not subjected to SUMO-dependent inhibition of telomerase and were elongated efficiently (17). These studies indirectly support the idea that relevant Siz2-specific targets are present at the nuclear periphery and hence only those functions are likely to be significantly altered by perturbing Siz2 function. We imagine that the normal sumoylating activity of Siz2 along with the desumoylating activity of Ulp1 at the nuclear periphery acts to maintain a balance of sumoylation/desumoylation that supports the localization of Sir2/Sir4 to these silent regions. This balance is perturbed in an esc1 strain due to delocalization of Ulp1. In conclusion, our studies provide a new perspective for investigating the molecular mechanisms that control the distribution of Sir2 protein within the nucleus and specifically point to a possible role for sumoylation in this process.

Supplementary Material

Supplemental material:

ACKNOWLEDGMENTS

We thank Yoshiko Kikuchi, S. Gasser, and R. Sternglanz for plasmids and strains, Nandini Rangarajan for help with confocal scanning, E. Johnson and H. Ferreira for advice on SUMO blots, and S. Banerjee for advice on statistics.

Funding for this work was from DST, DBT, CSIR, and UGC, India. D.S. acknowledges support from OncoSuisse, the Swiss National Science Foundation, and the Canton of Geneva.

Footnotes

Published ahead of print 17 February 2012

Supplemental material for this article may be found at http://ec.asm.org/.

REFERENCES

1. Andrulis ED, Neiman AM, Zappulla DC, Sternglanz R. 1998. Perinuclear localization of chromatin facilitates transcriptional silencing. Nature 394:592–595. [PubMed]
2. Andrulis ED, et al. 2002. Esc1, a nuclear periphery protein required for Sir4-based plasmid anchoring and partitioning. Mol. Cell. Biol. 22:8292–8301. [PMC free article] [PubMed]
3. Aparicio OM, et al. 1994. Overcoming telomeric silencing: a trans-activator competes to establish gene expression in a cell cycle-dependent way Silent domains are assembled continuously from the telomere and are defined by promoter distance and strength, and by SIR3 dosage. Genes Dev. 8:1133–1146. [PubMed]
4. Bose ME, et al. 2004. The origin recognition complex and Sir4 protein recruit Sir1p to yeast silent chromatin through independent interactions requiring a common Sir1p domain. Mol. Cell. Biol. 24:774–786. [PMC free article] [PubMed]
5. Branzei D, Vanoli F, Foiani M. 2008. SUMOylation regulates Rad18-mediated template switch. Nature 456:915–920. [PubMed]
6. Bryk M, et al. 1997. Transcriptional silencing of Ty1 elements in the RDN1 locus of yeast. Genes Dev. 11:255–269. [PubMed]
7. Buck SW, Shore D. 1995. Action of a RAP1 carboxy-terminal silencing domain reveals an underlying competition between HMR and telomeres in yeast. Genes Dev. 9:370–384. [PubMed]
8. Buhler M, Gasser SM. 2009. Silent chromatin at the middle and ends: lessons from yeasts. EMBO J. 28:2149–2161. [PMC free article] [PubMed]
9. Chen XL, Reindle A, Johnson ES. 2005. Misregulation of 2μm circle copy number in a SUMO pathway mutant. Mol. Cell. Biol. 25:4311–4320. [PMC free article] [PubMed]
10. Cheng CH, et al. 2006. SUMO modifications control assembly of synaptonemal complex and polycomplex in meiosis of Saccharomyces cerevisiae. Genes Dev. 20:2067–2081. [PubMed]
11. Chien CT, Buck S, Sternglanz R, Shore D. 1993. Targeting of SIR1 protein establishes transcriptional silencing at HM loci and telomeres in yeast. Cell 75:531–541. [PubMed]
12. Cuperus G, Shore D. 2002. Restoration of silencing in Saccharomyces cerevisiae by tethering of a novel Sir2-interacting protein, Esc8. Genetics 162:633–645. [PubMed]
12a. Cuperus G, Shafaatian R, Shore D. 2000. Locus specificity determinants in the multifunctional yeast silencing protein Sir2. EMBO J. 19:2641–2651. [PubMed]
13. Darst RP, Garcia SN, Koch MR, Pillus L. 2008. Slx5 promotes transcriptional silencing and is required for robust growth in the absence of Sir2. Mol. Cell. Biol. 28:1361–1372. [PMC free article] [PubMed]
14. Denison C, et al. 2005. A proteomic strategy for gaining insights into protein sumoylation in yeast. Mol. Cell Proteomics 4:246–254. [PubMed]
15. Dhillon N, Kamakaka RT. 2000. A histone variant, Htz1p, and a Sir1p-like protein, Esc2p, mediate silencing at HMR. Mol. Cell 6:769–780. [PubMed]
16. Donze D, Kamakaka RT. 2002. Braking the silence: how heterochromatic gene repression is stopped in its tracks. Bioessays 24:344–349. [PubMed]
17. Ferreira HC, et al. 2011. The PIAS homologue Siz2 regulates perinuclear telomere position and telomerase activity in budding yeast. Nat. Cell Biol. 13:867–874. [PubMed]
18. Fox CA, McConnell KH. 2005. Toward biochemical understanding of a transcriptionally silenced chromosomal domain in Saccharomyces cerevisiae. J. Biol. Chem. 280:8629–8632. [PubMed]
19. Gomez-del Arco P, Koipally J, Georgopoulos K. 2005. Ikaros SUMOylation: switching out of repression. Mol. Cell. Biol. 25:2688–2697. [PMC free article] [PubMed]
20. Gotta M, Laroche T, Gasser SM. 1999. Analysis of nuclear organization in Saccharomyces cerevisiae. Methods Enzymol. 304:663–672. [PubMed]
21. Gottschling DE, Aparicio OM, Billington BL, Zakian VA. 1990. Position effect at S. cerevisiae telomeres: reversible repression of Pol II transcription. Cell 63:751–762. [PubMed]
22. Grewal SI, Jia S. 2007. Heterochromatin revisited. Nat. Rev. Genet. 8:35–46. [PubMed]
23. Hannich JT, et al. 2005. Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J. Biol. Chem. 280:4102–4110. [PubMed]
24. Hecht A, Laroche T, Strahl-Bolsinger S, Gasser SM, Grunstein M. 1995. Histone H3 and H4 N-termini interact with SIR3 and SIR4 proteins: a molecular model for the formation of heterochromatin in yeast. Cell 80:583–592. [PubMed]
25. Hochstrasser M. 2001. SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 107:5–8. [PubMed]
26. Hoege C, Pfander B, Moldovan GL, Pyrowolakis G, Jentsch S. 2002. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419:135–141. [PubMed]
27. Johnson ES, Gupta AA. 2001. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 106:735–744. [PubMed]
28. Kagey MH, Melhuish TA, Wotton D. 2003. The polycomb protein Pc2 is a SUMO E3. Cell 113:127–137. [PubMed]
29. Laroche T, et al. 1998. Mutation of yeast Ku genes disrupts the subnuclear organization of telomeres. Curr. Biol. 8:653–656. [PubMed]
30. Lewis A, Felberbaum R, Hochstrasser M. 2007. A nuclear envelope protein linking nuclear pore basket assembly, SUMO protease regulation, and mRNA surveillance. J. Cell Biol. 178:813–827. [PMC free article] [PubMed]
31. Ling Y, et al. 2004. Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription. Nucleic Acids Res. 32:598–610. [PMC free article] [PubMed]
32. Longtine MS, et al. 1998. Additional modules for versatile and economical PCR-based gene deletion and modification in Saccharomyces cerevisiae. Yeast 14:953–961. [PubMed]
33. Marcand S, Buck SW, Moretti P, Gilson E, Shore D. 1996. Silencing of genes at nontelomeric sites in yeast is controlled by sequestration of silencing factors at telomeres by Rap 1 protein. Genes Dev. 10:1297–1309. [PubMed]
34. Melchior F, Schergaut M, Pichler A. 2003. SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28:612–618. [PubMed]
35. Mishra K, Shore D. 1999. Yeast Ku protein plays a direct role in telomeric silencing and counteracts inhibition by rif proteins. Curr. Biol. 9:1123–1126. [PubMed]
36. Moretti P, Shore D. 2001. Multiple interactions in Sir protein recruitment by Rap1p at silencers and telomeres in yeast. Mol. Cell. Biol. 21:8082–8094. [PMC free article] [PubMed]
37. Nathan D, et al. 2006. Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications. Genes Dev. 20:966–976. [PubMed]
38. Palancade B, Doye V. 2008. Sumoylating and desumoylating enzymes at nuclear pores: underpinning their unexpected duties? Trends Cell Biol. 18:174–183. [PubMed]
39. Panse VG, Hardeland U, Werner T, Kuster B, Hurt E. 2004. A proteome-wide approach identifies sumoylated substrate proteins in yeast. J. Biol. Chem. 279:41346–41351. [PubMed]
40. Pryde FE, Louis EJ. 1999. Limitations of silencing at native yeast telomeres. EMBO J. 18:2538–2550. [PubMed]
41. Reindle A, et al. 2006. Multiple domains in Siz SUMO ligases contribute to substrate selectivity. J. Cell Sci. 119:4749–4757. [PubMed]
42. Rossmann MP, Luo W, Tsaponina O, Chabes A, Stillman B. 2011. A common telomeric gene silencing assay is affected by nucleotide metabolism. Mol. Cell 42:127–136. [PMC free article] [PubMed]
43. Rusche LN, Kirchmaier AL, Rine J. 2003. The establishment, inheritance, and function of silenced chromatin in Saccharomyces cerevisiae. Annu. Rev. Biochem. 72:481–516. [PubMed]
44. Sacher M, Pfander B, Hoege C, Jentsch S. 2006. Control of Rad52 recombination activity by double-strand break-induced SUMO modification. Nat. Cell Biol. 8:1284–1290. [PubMed]
45. Smith JS, Boeke JD. 1997. An unusual form of transcriptional silencing in yeast ribosomal DNA. Genes Dev. 11:241–254. [PubMed]
46. Smith JS, Brachmann CB, Pillus L, Boeke JD. 1998. Distribution of a limited Sir2 protein pool regulates the strength of yeast rDNA silencing and is modulated by Sir4p. Genetics 149:1205–1219. [PubMed]
47. Strahl-Bolsinger S, Hecht A, Luo K, Grunstein M. 1997. SIR2 and SIR4 interactions differ in core and extended telomeric heterochromatin in yeast. Genes Dev. 11:83–93. [PubMed]
48. Straight AF, et al. 1999. Net1, a Sir2-associated nucleolar protein required for rDNA silencing and nucleolar integrity. Cell 97:245–256. [PubMed]
49. Sussel L, Vannier D, Shore D. 1995. Suppressors of defective silencing in yeast: effects on transcriptional repression at the HMR locus, cell growth and telomere structure. Genetics 141:873–888. [PubMed]
50. Taddei A, Hediger F, Neumann FR, Bauer C, Gasser SM. 2004. Separation of silencing from perinuclear anchoring functions in yeast Ku80, Sir4 and Esc1 proteins. EMBO J. 23:1301–1312. [PubMed]
51. Takahashi Y, Toh EA, Kikuchi Y. 2003. Comparative analysis of yeast PIAS-type SUMO ligases in vivo and in vitro. J. Biochem. 133:415–422. [PubMed]
52. Takahashi YH, et al. 2011. Dot1 and histone H3K79 methylation in natural telomeric and HM silencing. Mol. Cell 42:118–126. [PMC free article] [PubMed]
52a. Thomas BJ, Rothstein R. 1989. Elevated recombination rates in transcriptionally active DNA. Cell 56:619–630. [PubMed]
53. Triolo T, Sternglanz R. 1996. Role of interactions between the origin recognition complex and SIR1 in transcriptional silencing. Nature 381:251–253. [PubMed]
54. White SA, Allshire RC. 2008. RNAi-mediated chromatin silencing in fission yeast. Curr. Top. Microbiol. Immunol. 320:157–183. [PubMed]
55. Wilkinson KA, Henley JM. 2010. Mechanisms, regulation and consequences of protein SUMOylation. Biochem. J. 428:133–145. [PMC free article] [PubMed]
56. Wohlschlegel JA, Johnson ES, Reed SI, Yates JR., III 2004. Global analysis of protein sumoylation in Saccharomyces cerevisiae. J. Biol. Chem. 279:45662–45668. [PubMed]
56a. Wotton D, Shore D. 1997. A novel Rap1p-interacting factor, Rif2p, cooperates with Rif1p to regulate telomere length in Saccharomyces cerevisiae. Genes Dev. 11:748–760. [PubMed]
57. Wu SY, Chiang CM. 2009. Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. EMBO J. 28:1246–1259. [PubMed]
58. Xhemalce B, Seeler JS, Thon G, Dejean A, Arcangioli B. 2004. Role of the fission yeast SUMO E3 ligase Pli1p in centromere and telomere maintenance. EMBO J. 23:3844–3853. [PubMed]
59. Xu EY, Zawadzki KA, Broach JR. 2006. Single-cell observations reveal intermediate transcriptional silencing states. Mol. Cell 23:219–229. [PubMed]
60. Xu F, Zhang Q, Zhang K, Xie W, Grunstein M. 2007. Sir2 deacetylates histone H3 lysine 56 to regulate telomeric heterochromatin structure in yeast. Mol. Cell 27:890–900. [PMC free article] [PubMed]
61. Yang B, Kirchmaier AL. 2006. Bypassing the catalytic activity of SIR2 for SIR protein spreading in Saccharomyces cerevisiae. Mol. Biol. Cell 17:5287–5297. [PMC free article] [PubMed]
62. Yeh ET. 2009. SUMOylation and de-SUMOylation: wrestling with life's processes. J. Biol. Chem. 284:8223–8227. [PubMed]
63. Yu Q, et al. 2010. Saccharomyces cerevisiae Esc2p interacts with Sir2p through a small ubiquitin-like modifier (SUMO)-binding motif and regulates transcriptionally silent chromatin in a locus-dependent manner. J. Biol. Chem. 285:7525–7536. [PubMed]
64. Zhao J. 2007. Sumoylation regulates diverse biological processes. Cell. Mol. Life Sci. 64:3017–3033. [PubMed]
65. Zhao X, Blobel G. 2005. A SUMO ligase is part of a nuclear multiprotein complex that affects DNA repair and chromosomal organization. Proc. Natl. Acad. Sci. U. S. A. 102:4777–4782. [PubMed]
66. Zhou W, Ryan JJ, Zhou H. 2004. Global analyses of sumoylated proteins in Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses. J. Biol. Chem. 279:32262–32268. [PMC free article] [PubMed]

Articles from Eukaryotic Cell are provided here courtesy of American Society for Microbiology (ASM)